Clinical Hours: Mon-Fri, 8AM - 3PM(905) 493-5700
1885 Glenanna Road, Suite 220, Pickering, ON, L1V 6R6
Dermatomyositis is an autoimmune inflammatory myopathy with characteristic cutaneous findings including Gottron papules and heliotrope rash, requiring specialist evaluation.
Dermatomyositis is an idiopathic inflammatory myopathy characterised by distinctive cutaneous manifestations that may accompany, precede, or occur independently of skeletal muscle inflammation. The condition belongs to a group of autoimmune diseases collectively known as inflammatory myopathies, and its hallmark skin findings are among the most recognisable in dermatology.
Dermatomyositis can affect both adults and children, with the adult form carrying an important association with underlying malignancy. Clinically amyopathic dermatomyositis (previously termed amyopathic dermatomyositis) describes a subset of patients who present with the characteristic skin findings but without clinically evident muscle disease. Recognition of the cutaneous features is essential for early diagnosis, appropriate investigation, and timely initiation of treatment.
The pathogenesis of dermatomyositis involves an autoimmune-mediated process directed against small blood vessels in the skin and muscle. The resulting complement-mediated microangiopathy leads to tissue ischaemia and damage. Myositis-specific autoantibodies (MSAs) have been identified in a large proportion of patients and are increasingly used to define clinical subtypes, predict disease course, and guide treatment.
Key risk factors and associations include:
Juvenile dermatomyositis, which presents in childhood, is not associated with malignancy but may be complicated by calcinosis (calcium deposits in the skin and soft tissues) if not treated promptly.
The cutaneous findings of dermatomyositis are highly distinctive and often serve as the initial presenting feature. The skin manifestations can be broadly categorised into pathognomonic, characteristic, and associated findings.
When muscle involvement is present, patients typically experience symmetrical proximal muscle weakness affecting the shoulders, upper arms, hips, and thighs. Common functional complaints include difficulty rising from a seated position, climbing stairs, lifting objects overhead, and combing hair. Dysphagia (difficulty swallowing) may occur due to involvement of the oropharyngeal and oesophageal muscles. Interstitial lung disease is an important extramuscular manifestation, particularly in patients with anti-MDA5 or anti-aminoacyl-tRNA synthetase antibodies.
The diagnosis of dermatomyositis is based on recognition of the characteristic cutaneous findings in conjunction with supportive laboratory, histopathological, and imaging data. A skin biopsy of an affected area reveals an interface dermatitis pattern with vacuolar change at the dermal-epidermal junction, perivascular lymphocytic infiltrate, and increased dermal mucin deposition. The histopathological findings may overlap with those of cutaneous lupus, and clinical correlation is essential.
Nail fold capillaroscopy, which can be performed with dermoscopy, may reveal dilated, tortuous capillary loops with areas of capillary dropout at the nail folds, a finding that supports the diagnosis and can be useful for monitoring disease activity.
Laboratory investigations include muscle enzymes (creatine kinase, aldolase, lactate dehydrogenase), myositis-specific antibody panel (anti-Mi-2, anti-MDA5, anti-TIF1-gamma, anti-NXP-2, anti-SAE, anti-aminoacyl-tRNA synthetases), and inflammatory markers. Electromyography (EMG) and MRI of affected muscle groups may demonstrate characteristic patterns of inflammation. Given the association with malignancy in adults, age-appropriate cancer screening is an essential component of the diagnostic workup.
The management of dermatomyositis requires a coordinated approach addressing both the skin disease and any muscle or systemic involvement. Treatment is guided by disease severity, the antibody profile, and the presence or absence of associated conditions such as interstitial lung disease or malignancy.
Strict UV avoidance is a critical component of managing the cutaneous manifestations of dermatomyositis. Daily application of broad-spectrum sunscreen with high SPF, sun-protective clothing, and behavioural sun avoidance are essential, as UV exposure is a potent trigger for skin disease flares.
Topical corticosteroids and topical calcineurin inhibitors are used to manage localised skin disease. These agents can reduce erythema and pruritus and are particularly useful for facial involvement, where prolonged potent corticosteroid use carries a risk of atrophy. Topical therapy alone is rarely sufficient for controlling the skin disease in most patients and is typically used as an adjunct to systemic treatment.
Systemic corticosteroids are often used initially to control active muscle and skin disease. Steroid-sparing immunosuppressants are introduced early to allow corticosteroid tapering and to maintain long-term disease control. Commonly used agents include methotrexate, azathioprine, and mycophenolate mofetil. Intravenous immunoglobulin (IVIG) is an effective option for refractory muscle disease and severe skin involvement. Hydroxychloroquine may be used for isolated skin-predominant disease, although dermatomyositis skin disease is sometimes resistant to antimalarials. All systemic therapies are managed through a structured prescription management programme with regular monitoring of blood counts, liver and kidney function, and disease activity markers.
Rituximab, a monoclonal antibody targeting CD20-positive B cells, is used in refractory dermatomyositis and has shown efficacy in both muscle and skin disease. Janus kinase (JAK) inhibitors are an emerging therapeutic class that have demonstrated promising results in the treatment of dermatomyositis skin disease, particularly in patients with refractory cutaneous involvement. These advanced therapies may be considered through the biologic and advanced small molecule therapy programme when standard treatments are insufficient.
Medical evaluation is recommended for any unexplained skin rash with features suggestive of dermatomyositis, including violaceous discolouration of the eyelids, papules over the knuckles, or photosensitive eruptions on the chest, back, or shoulders. The combination of skin rash with progressive muscle weakness, difficulty swallowing, or shortness of breath warrants urgent assessment. Early diagnosis is particularly important given the association with internal malignancy in adults and the potential for rapidly progressive interstitial lung disease in certain antibody subtypes.
A referral from a family physician is the standard pathway to access specialist dermatology care. Dr. Maksym Breslavets at the Centre for Medical and Surgical Dermatology provides specialist evaluation and management of dermatomyositis, including diagnostic biopsy, nail fold capillaroscopy, and coordination of immunosuppressive therapy.
Your feedback helps us improve our condition information
A physician referral is required to access our medical services. Contact your primary care provider to begin the referral process.